EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants

Catherine M Moore, Mathew J Paul, Elizabeth Pinneh, Balamurugan Shanmugaraj, James Ashall, Sathishkumar Ramalingam, Roger Hewson, Michael S Diamond, Julie M Fox, Julian K-C Ma

Journal of Biotechnology · 2025

DOI: 10.1016/j.jbiotec.2025.06.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biotechnology, 2025. Verfasst von Catherine M Moore und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hotung Molecular Immunology Unit, Institute for Infection & Immunity, St George's University of London, Cranmer Terrace, London SW17 0RE, UK. Electro…. Hauptthemen laut MEDLINE: Nicotiana, Chikungunya virus, Antibodies, Monoclonal, Antibodies, Neutralizing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, UK-India Education and Research Initiative, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chikungunya virus (CHIKV) causes a debilitating musculoskeletal disease, characterised by flu-like symptoms, rash, and severe joint pain, which can last for months, even after the resolution of infection. Although the first CHIKV vaccine was approved in the USA in 2023 for use in adults, there is currently no specific antiviral therapy for infection. While neutralising antibody-based prophylactic and therapeutic agents have been considered, affordability and accessibility are major barriers to global regions where Chikungunya disease is epidemic. Here, we expressed five anti-CHIKV neutralising IgG monoclonal antibodies (mAbs) in N. benthamiana plants to investigate the potential use of this manufacturing platform. Plants produced IgG mAbs that compared favourably to mammalian cell-expressed antibodies, including for binding kinetics to CHIKV antigens and neutralisation activity. The yields of mAbs from plants were variable, as three of the antibodies' yields would need further expression optimisation to warrant future development. The successful expression of these antibodies in N. benthamiana plants supports the growing pipeline of Global Health product targets that could be developed using a highly transferable, low-cost, low-tech plant production platform in resource-poor countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NicotianaChikungunya virusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralPlants, Genetically ModifiedChikungunya FeverAnimalsHumansImmunoglobulin G

Stichwörter der Autor:innen

ChikungunyaImmunotherapyMolecular pharmingMonoclonal antibodiesPlants

Substanzen

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • Hotung Molecular Immunology Unit, Institute for Infection & Immunity, St George's University of London, Cranmer Terrace, London SW17 0RE, UK. Electronic address: c.moore@westminster.ac.uk.
  • Hotung Molecular Immunology Unit, Institute for Infection & Immunity, St George's University of London, Cranmer Terrace, London SW17 0RE, UK.
  • Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu 641046, India.
  • London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK; WHO-Collaborating Centre Virus Reference & Research (Special Pathogens), Salisbury SP4 0JG, UK; UK Health Security Agency, Porton Down, S…
  • Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Emerging Virus Immunity Unit, Laboratory of Viral Diseases, National Institute Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Förderung

  • Horizon 2020
  • UK-India Education and Research Initiative
  • National Institute of Allergy and Infectious Diseases
  • Horizon 2020 Framework Programme
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research

Zitieren

APA

Moore, C. M., Paul, M. J., Pinneh, E., Shanmugaraj, B., Ashall, J., Ramalingam, S., Hewson, R., Diamond, M. S., Fox, J. M., & Ma, J. K. (2025). Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants. Journal of Biotechnology. https://doi.org/10.1016/j.jbiotec.2025.06.014

Vancouver

Moore CM, Paul MJ, Pinneh E, Shanmugaraj B, Ashall J, Ramalingam S, et al. Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants. Journal of Biotechnology. 2025. doi:10.1016/j.jbiotec.2025.06.014

BibTeX
@article{Moore2025,
  author = {Moore, Catherine M and Paul, Mathew J and Pinneh, Elizabeth and Shanmugaraj, Balamurugan and Ashall, James and Ramalingam, Sathishkumar and Hewson, Roger and Diamond, Michael S and Fox, Julie M and Ma, Julian K-C},
  title = {Characterisation of chikungunya virus neutralising monoclonal antibodies expressed in tobacco plants},
  journal = {Journal of Biotechnology},
  year = {2025},
  doi = {10.1016/j.jbiotec.2025.06.014}
}
Kostenlos starten →